HSD11B1 Gene and Its Potential Therapeutic Applications (G3290)

Target Name: HSD11B1

NCBI ID: G3290

HSD11B1

HSD11B1 Gene and Its Potential Therapeutic Applications

HSD11B1 (HSD11B1 variant 3) is a gene that encodes a protein known as protamine-2 (P2), which is a key component of the brush border of the mitochondria. Mitochondria are organelles that are found in the cells of all eukaryotes, and they are responsible for generating the energy that cells need to function. The protein encoded by the HSD11B1 gene is involved in a variety of cellular processes, including the metabolism of lipids and the production of ATP.

One of the unique features of HSD11B1 is its ability to cause a disease known as鈥? inclusion body disease鈥? in mice. This disease is characterized by the accumulation of misfolded proteins in the mitochondria, which can cause a build-up of toxic substances in the cells. In addition, HSD11B1 has also been shown to be involved in the development of certain types of cancer.

The HSD11B1 gene has also been identified as a potential drug target. By targeting the protein encoded by this gene, researchers may be able to interfere with its function and potentially treat a variety of diseases. One way that this could be done is through the use of small molecules, such as drugs that bind to specific regions of the HSD11B1 protein. These drugs could then be administered to the cells to reduce the activity of the protein and potentially inhibit its function.

Another approach that researchers might take to target HSD11B1 is through the use of antibodies. Antibodies are proteins that are produced by the immune system and are designed to recognize and neutralize foreign substances like viruses or bacteria. By creating antibodies that are specific for the HSD11B1 protein, researchers could potentially use these antibodies to target the protein in the cells and reduce its activity.

In addition to these potential therapeutic approaches, researchers are also interested in studying the HSD11B1 gene and its function in more detail. This is because understanding how the HSD11B1 protein is produced and how it functions in the cells could have important implications for the development of new treatments for a variety of diseases.

Overall, HSD11B1 (HSD11B1 variant 3) is a gene that has the potential to be a drug target or biomarker. Its unique ability to cause inclusion body disease and its involvement in the development of certain types of cancer make it an attractive target for researchers to study. Additionally, the development of antibodies and small molecules that can specifically target the HSD11B1 protein could have important implications for the development of new treatments for a variety of diseases.

Protein Name: Hydroxysteroid 11-beta Dehydrogenase 1

Functions: Controls the reversible conversion of biologically active glucocorticoids such as cortisone to cortisol, and 11-dehydrocorticosterone to corticosterone in the presence of NADP(H) (PubMed:10497248, PubMed:12460758, PubMed:14973125, PubMed:15152005, PubMed:15280030, PubMed:17593962, PubMed:21453287, PubMed:27927697, PubMed:30902677). Participates in the corticosteroid receptor-mediated anti-inflammatory response, as well as metabolic and homeostatic processes (PubMed:12414862, PubMed:10497248, PubMed:15152005, PubMed:21453287). Plays a role in the secretion of aqueous humor in the eye, maintaining a normotensive, intraocular environment (PubMed:11481269). Bidirectional in vitro, predominantly functions as a reductase in vivo, thereby increasing the concentration of active glucocorticoids (PubMed:12414862, PubMed:10497248, PubMed:11481269, PubMed:12460758). It has broad substrate specificity, besides glucocorticoids, it accepts other steroid and sterol substrates (PubMed:15095019, PubMed:15152005, PubMed:17593962, PubMed:21453287). Interconverts 7-oxo- and 7-hydroxy-neurosteroids such as 7-oxopregnenolone and 7beta-hydroxypregnenolone, 7-oxodehydroepiandrosterone (3beta-hydroxy-5-androstene-7,17-dione) and 7beta-hydroxydehydroepiandrosterone (3beta,7beta-dihydroxyandrost-5-en-17-one), among others (PubMed:17593962). Catalyzes the stereo-specific conversion of the major dietary oxysterol, 7-ketocholesterol (7-oxocholesterol), into the more polar 7-beta-hydroxycholesterol metabolite (PubMed:15095019, PubMed:15152005). 7-oxocholesterol is one of the most important oxysterols, it participates in several events such as induction of apoptosis, accumulation in atherosclerotic lesions, lipid peroxidation, and induction of foam cell formation (PubMed:15095019). Mediates the 7-oxo reduction of 7-oxolithocholate mainly to chenodeoxycholate, and to a lesser extent to ursodeoxycholate, both in its free form and when conjugated to glycine or taurine, providing a link between glucocorticoid activation and bile acid metabolism (PubMed:21453287). Catalyzes the synthesis of 7-beta-25-dihydroxycholesterol from 7-oxo-25-hydroxycholesterol in vitro, which acts as ligand for the G-protein-coupled receptor (GPCR) Epstein-Barr virus-induced gene 2 (EBI2) and may thereby regulate immune cell migration (PubMed:30902677)

The "HSD11B1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HSD11B1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets